Advertisement
Mergers and Acquisitions
Subscribe to Mergers and Acquisitions

The Lead

DPx Holdings B.V. Reaches Definitive Agreement to Acquire Gallus BioPharmaceuticals

August 28, 2014 11:55 am | News | Comments

DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners.

Novo Nordisk Buys Production Plant in New Hampshire

August 28, 2014 11:47 am | News | Comments

The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in...

Cilag GmbH International Acquires Covagen AG

August 25, 2014 8:41 am | News | Comments

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson &...

VIVUS Acquires Topiramate-Related Patents From Janssen Pharmaceuticals

August 25, 2014 8:29 am | News | Comments

VIVUS today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc....

View Sample

FREE Email Newsletter

Roche to Buy InterMune for $8.3B

August 25, 2014 8:10 am | News | Comments

Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.                   

Allergan Reviews Meeting Requests in Takeover Bid

August 23, 2014 2:27 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly...

Allergan Acquires LiRIS® Program from TARIS Biomedical®

August 14, 2014 8:43 am | News | Comments

Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical's® lead program, LiRIS®, which is currently in Phase 2 trials for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).      

Advertisement

Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino

August 12, 2014 8:39 am | News | Comments

Valeant Pharmaceuticals International  announced that the company has received a request for additional information from the Federal Trade Commission in connection with Valeant's proposed acquisition of Allergan, Inc.      

Tekni-Plex to Acquire Closure Liner and Seal Manufacturer Tech-Seal

August 7, 2014 1:55 pm | News | Comments

Tekni-Plex, Inc. announced today that it has signed an agreement to acquire the assets of Tech-Seal Products, Inc. Tech-Seal manufactures closure liners and innerseals for food, pharmaceutical, cosmetic, and industrial applications.     

Takeda President: Company to Extend Global Reach Through Acquisitions

August 7, 2014 8:37 am | News | Comments

New Takeda Pharmaceutical Company President Christophe Weber said recently that Japan's biggest drugmaker will continue efforts to expand its business abroad through acquisitions and will outline a new strategy by the end of the year.   

Alvogen Acquires Korean Dream Pharma for $187M

August 6, 2014 8:22 am | News | Comments

Alvogen announced today that it has acquired Dream Pharma in South Korea for $187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea.

Walgreens and Alliance Boots Accelerate Efforts to Fully Combine Both Companies

August 6, 2014 8:07 am | News | Comments

Walgreens today said it has exercised its option to complete the second step of its strategic transaction with Alliance Boots GmbH ahead of the original option period, which was between February and August 2015. The transaction, subject to shareholder and various regulatory approvals, would fully combine the two companies to form the first global pharmacy-led, health and wellbeing enterprise.

Advertisement

Allergan Sues Valeant, Claims Fraud in Buy Attempt

August 1, 2014 3:34 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Allergan Inc.'s lawsuit, filed Friday in U.S. District Court in Santa Ana, California, names as plaintiffs drugmaker Valeant Pharmaceuticals International Inc., New York investment and hedge fund firm Pershing Square Capital Management LP and its principal, William Ackerman.

Meda to Acquire Rottapharm

July 31, 2014 8:14 am | News | Comments

Meda announced today that it has entered into a definitive agreement to acquire Rottapharm/Madaus, an Italian company owned by the Rovati family, for a consideration of SEK 21.2 billion on a cash and debt free basis.      

AstraZeneca to Acquire Almirall's Respiratory Disease Business

July 30, 2014 8:11 am | News | Comments

AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones.

Baxter to Sell Commercial Vaccines Business to Pfizer

July 30, 2014 8:06 am | News | Comments

Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of $635 million, subject to certain adjustments.   

PaxVax Acquires FDA-Approved Typhoid Vaccine Vivotif

July 28, 2014 9:19 am | News | Comments

PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG, as well as its manufacturing facility in Thörishaus, near Bern, Switzerland.

Advertisement

Valeant Takes Allergan Complaints to Regulators

July 21, 2014 8:23 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. is complaining to regulators that Botox maker and acquisition target Allergan has been making false statements about its business.             

Teva Completes Acquisition of Labrys

July 21, 2014 8:15 am | News | Comments

The acquisition of Labrys brings to Teva LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), which is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine.  

GTCR to Acquire Cole-Parmer Instrument Company

July 17, 2014 1:55 pm | News | Comments

GTCR, a private equity firm, has entered into a definitive agreement to acquire the Cole-Parmer Instrument Company from Thermo Fisher Scientific Inc. for $480 million. Cole-Parmer, headquartered in Vernon Hills, Illinois, is a global manufacturer and distributor of specialty laboratory equipment, instruments and supplies to a diverse range of industries.

Pfizer to Acquire InnoPharma

July 16, 2014 9:34 am | News | Comments

Pfizer and InnoPharma, a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

Chiltern Acquires Ockham - Companies Merge Operations

July 15, 2014 11:45 am | News | Comments

Chiltern and Ockham, two full-service contract research organizations (CROs), today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations. The combined company will be called Chiltern. Ockham's management team will join the management of the enlarged group, thus ensuring a seamless continuation of high quality services.

Anthera Pharmaceuticals Acquires Sollpur for Exocrine Pancreatic Insufficiency From Eli Lilly

July 15, 2014 9:04 am | News | Comments

Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases.   

Mylan to Buy Abbott's Generic Drugs Business in $5.3B Deal

July 14, 2014 8:17 am | News | Comments

Mylan said Monday that the deal will diversify and expand its business outside the U.S. The combined company will be organized in the Netherlands, which will help reduce its tax expenses, while maintaining its headquarters near Pittsburgh.  

AbbVie, Shire Enter Detailed Talks on Combination

July 14, 2014 7:27 am | by The Associated Press | News | Comments

AbbVie and Shire are in detailed talks about a possible combination after AbbVie once again raised the deal price and gave Shire shareholders a bigger stake in the new company. Shire says North Chicago, Illinois-based AbbVie is now offering a cash-stock combination valued at 53.20 British pounds ($91.10) for each share of Shire, which is headquartered on the British island of Jersey.

US to Lead the Megadeal Charge for Second Half of 2014

July 11, 2014 8:52 am | News | Comments

Multi-billion dollar deals across a variety of sectors dominated headlines throughout the first half of 2014, and despite virtually flat US deal volumes rising deal values could be indicative of an M&A rebound to come, according to EY Transaction Advisory Services.

Galderma Finalizes Major Expansion in Aesthetic and Corrective Dermatology in the U.S. and Canada

July 11, 2014 8:13 am | News | Comments

Galderma S.A. announced that it has gained full rights to distribute Restylane, Perlane, Emervel, Sculptra and Dysport from Valeant Pharmaceuticals International, Inc. The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma's global skin health footprint and extends its leadership in aesthetic medicine worldwide.

More 'Headline-Grabbing' Corporate Deals Expected

July 10, 2014 8:29 am | by PAN PYLAS, Associated Press | News | Comments

More "headline-grabbing" acquisitions are likely over the coming year as businesses take advantage of a period of improving economic growth and cheap financing. That's the conclusion of business consulting firm EY, which says the value of takeover deals announced in the first half of 2014 struck its highest level since the end of the boom years in 2007.

Baxter Acquires AesRx, LLC, Including Its Investigational Sickle Cell Disease Treatment

July 9, 2014 9:08 am | News | Comments

Baxter International Inc. announces the acquisition of AesRx, LLC, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD).

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading